ClinicalTrials.gg
CompletedNCT05856513Updated Dec 1, 2023

Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment

A Phase 1 interventional study of ZSP1273 and ZSP1273 in Hepatic Impairment and Pharmacokinetics, sponsored by Guangdong Raynovent Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 68 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 68 Years
Sex
All
01

Study summary

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of ZSP1273.

02

Conditions studied

  • Hepatic Impairment
  • Pharmacokinetics
03

In context

Lead sponsor

Guangdong Raynovent Biotech Co., Ltd is the lead sponsor of 36 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 to ≤ 68 years, at the time of signing the .
  2. ≥ 18 kg/m2 up to ≤ 32 kg/m2.
  3. Participants (including partners) must use reliable methods of during the study and until 3 months following the last dose of product.
  4. Signature of a dated Informed Consent Form (ICF) indicating that the participates has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.

    Participants with hepatic impairment only:

  5. Supporting documents confirming that the participant has liver cirrhosis with hepatic impairment must be available.
  6. Unless otherwise stated, participants must have been on stable doses and regimens of the concomitant medication for at least 4 weeks before screening, or treatment-naïve participants

Exclusion criteria

Exclusion Criteria:

  1. Participants with an allergic disposition (multiple drug and food allergies) or who, as determined by the investigator, are likely to be allergic to the drug product or any component of the investigational drug product.
  2. (male) > 470ms,QTcF (female) > 480ms
  3. Participants with serious infections, trauma, gastrointestinal surgery or other major surgical procedures within 4 weeks
  4. Participants who donated blood or bleeding profusely (> 400 mL) in the 3 months.
  5. Pregnant or lactating women, or women of childbearing age with a positive pregnancy test
  6. Smoking averaged more than 10 cigarettes per day in the 3 months prior to screening

    Participants with Normal Hepatic Function Only:

  7. Any history of hepatic impairment, or potential presence of liver function impairment by physical examination and laboratory examination at screening.

    Participants with Hepatic Impairment Only:

  8. Any history of clinically serious illness or disease or condition except for primary liver disease that the investigator believes may affect the results of the trial, including but not limited to a history of circulatory, endocrine, nervous, digestive, urinary, respiratoryor hematological, immune, psychiatric, and metabolic disorders.
  9. Participants with drug-induced liver injury; history of liver transplantation; cirrhosis in combination with the following complications: including but not limited to liver failure, hepatic encephalopathy, hepatocellular carcinoma, esophageal bleeding from ruptured fundic varices
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Child-Pugh A

    8 participants with mild hepatic impairment (Child-Pugh A) will be given 600mg of ZSP1273.

    Drug: ZSP1273

  • Experimental
    Child-Pugh B

    8 participants with moderate hepatic impairment (Child-Pugh B) will be given 600mg of ZSP1273.

    Drug: ZSP1273

  • Experimental
    Normal hepatic function

    8 participants with normal hepatic function will be given 600mg of ZSP1273.

    Drug: ZSP1273

Interventions

  • Participants receive ZSP1273 orally.

  • Participants receive ZSP1273 orally.

  • Participants receive ZSP1273 orally.

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    The Cmax of a single dose of ZSP1273 in participants with impaired hepatic function and controls with normal hepatic function will be evaluated and compared.

    Time frame: Day 1 to Day 6

  2. Area under the concentration-time curve from time zero to infinity (AUCinf)

    The AUCinf of a single dose of ZSP1273 in participants with impaired hepatic function and controls with normal hepatic function will be evaluated and compared.

    Time frame: Day 1 to Day 6

  3. Area under the concentration-time curve from time zero to last time of quantifiable concentration (AUClast)

    The AUClast of a single dose of ZSP1273 in participants with impaired hepatic function and controls with normal hepatic function will be evaluated and compared.

    Time frame: Day 1 to Day 6

Secondary outcomes

  1. Number of participants with drug-related adverse events as assessed by CTCAE v5.0

    Time frame: Day 1 to Day12

07

Study locations

1 site
  • The First Hospital of Jilin University
    Jilin, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2023
First posted
May 12, 2023
StartActual
Jun 15, 2023
Primary completionActual
Jul 4, 2023
CompletionActual
Jul 4, 2023
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05856513
Responsible party
Sponsor
First posted
May 12, 2023
Start date
Jun 15, 2023
Primary completion
Jul 4, 2023
Completion
Jul 4, 2023
Last update
Dec 1, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZSP1273

Start the discussion